Amgen and Illumina-backed genetic sequencing technology developer Oxford Nanopore is reportedly eyeing a $2.1bn private placement.
Tencent has led a series E-plus round for Taimei as part of a capital influx totalling $212m, with SoftBank's SBCVC unit also among the investors.
Each Friday the Global Corporate Venturing Deal Net rounds up the week’s smaller deals and tracks the emerging companies accessing corporate funds.
Tigermed has put up $12m for biotech-oriented fund TG Sino-Dragon Fund, which is also backed by Temasek and which has set a $62m target for its final close.
Clinical research partner dMed has completed a series B round that included returning investor Lilly Asia Ventures as it seeks to expand internationally.
Takeda is set to emerge with almost 26% of Phathom Pharmaceuticals, which has licensed one of its gastrointestinal disease drugs, and which is targeting $158m.
ProMedica and Pacira are both in line for exits after surgical implant producer Tela Bio filed for an initial public offering.
Intel Capital was among the participants in a round that lifted the total raised by rare disease-focused drug developer Healx to nearly $70m.